OTCQB: IGXT | TSX-V: IGX

About IntelGenx

IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films.

IntelGenx’s superior film technologies, including VersaFilm®, VetaFilm™ and VevaDerm™, allow for next generation pharmaceutical products that address unmet medical needs. IntelGenx’s innovative product pipeline offers significant benefits to patients and physicians for many therapeutic conditions.

IntelGenx's highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx's state-of-the-art manufacturing facility offers full service by providing lab-scale to pilot- and commercial-scale production. For more information, visit www.intelgenx.com.


 


 

Facts and figures

  • Sponsored 38 clinical studies, 7 pivotal studies and one phase 2 clinical trial.
  • Our employees have nearly 90 years of combined formulation experience
  • Our employees have more than 50 years of combined analytical experience
  • We have screened more than 100 small molecules for film applicability

 

Dr Horst Zerbe Aug 8 2016 Web LAS8124 00000002

Horst G. Zerbe, Ph.D.,Dr. Zerbe is the founder of IntelGenx Corp. and has been the Chief Executive Officer, and Chairman of IntelGenx Technologies Corp. since April 2006. In addition, Dr. Zerbe has served as the Chief Executive Officer and Director of IntelGenx Corp., our Canadian Subsidiary, since 2005. He also served as President of both entities until May 2019. Dr. Zerbe retired from his positions as President and Chief Executive Officer on January 1, 2014, and at the request of the Board, was re-appointed as President and CEO effective July 15, 2014.

Dr. Zerbe has more than 35 years of experience in the pharmaceutical industry. He started his career at Schwarz Pharma and subsequently at 3M Pharmaceuticals in Germany. From 1998 to 2005, he served as the President of Smartrix Technologies Inc. in Montreal; prior thereto, from 1994 to 1998, he served as Vice President of R&D and Technology Transfer at LTS Lohmann Therapy Systems in West Caldwell, NJ. During his assignments at 3M and LTS, he gained considerable experience in the technology transfer and commercial manufacturing of transdermal as well as oral film products. Dr. Zerbe has extensive executive level experience, and has been responsible for many strategic and business initiatives. Dr. Zerbe has been involved in new drug development and the acquisition and disposition of new drug candidates and other technology, licensing and distribution matters. He has published numerous scientific papers in recognized journals and holds more than 30 patents.

Our Board believes that both Dr. Zerbe’s length and breadth of industry-specific technical and business experience, and his role as founder and Chief Executive Officer of our subsidiary, IntelGenx Corp., qualifies him to serve on our Board of Directors. Dr. Zerbe was responsible for developing the vision of our company and identifying many of our current partner relationships.

Bernie Boudreau Aug 8 2016 LAS8129

J. Bernard Boudreau, QC, PC, Mr. Boudreau has been a director of IntelGenx Technologies Corp. since June 2006 and Vice Chairman of the Board since March 2014. From 2005 to 2008, Mr. Boudreau served as the Vice-President of Pharmeng International Inc., a pharmaceutical manufacturing and consulting company listed on the Toronto Stock Exchange. Since 2001, he has been President and CEO of Radcliffe Consulting and Investment Limited, a private consulting firm located in Halifax, N.S. From 2010 to 2013 he served on the board of directors at Pillar5 Pharma, a privately-owned Canadian Company, which was also previously one of our manufacturing partners. Mr. Boudreau has also served on the Board of Directors of a number of public and private companies, including Export Development Canada and the Bank of Canada.

Mr. Boudreau has a distinguished record as a lawyer, businessman and public figure. His litigation experience includes successful appearances at every level of the judicial system in Nova Scotia. He was appointed as Queen's Counsel in 1985. Mr. Boudreau was first elected to the provincial legislature of Nova Scotia in 1988. He served as Chair of the Public Accounts Committee and opposition critic for Finance and Economic Development. In 1993, he was re-elected as a member of government and held responsibilities as Minister of Finance, Minister of Health, Chair of the Cabinet Priorities and Planning Committee. Mr. Boudreau served as Government Leader in the Senate of Canada and Member of the federal Cabinet between 1999 and 2001.

Our Board believes that Mr. Boudreau’s service as a director for a number of public and private companies and his broad experience with governance issues facing public companies, qualifies him to serve on our Board of Directors. The Board also believes his extensive business and legal experience both inside and outside of our industry help him bring technical and non-technical perspectives when handling matters arising before the Board.

John Marinucci Aug 8 2016 LAS8130

John Marinucci, C.A., C.P.A., Mr. Marinucci has been a Director of IntelGenx Technologies Corp. since August 2010. From April 2002 until March 2009, Mr. Marinucci was President and Chief Executive Officer at New Flyer Industries Inc. (NFI), a publicly traded company listed on the Toronto Stock Exchange. During his seven-year tenure with New Flyer, Mr. Marinucci successfully restructured its manufacturing operations and the aftermarket services business, transforming New Flyer into the North American leader in the heavy-duty transit market. Under his leadership, New Flyer completed its IPO in August 2005 and successfully completed secondary offerings in July 2007 and April 2008. Mr. Marinucci retired from this position on March 31, 2009 and remains on the Board of Directors. Prior to this he was, from March 1994 to April 2002, President and Chief Operating Officer at National Steel Car Limited (NSC) and is a former President of the Canadian Association of Railway Suppliers. He is the past Chair of CWB group and of Mohawk College. Currently, Mr. Marinucci is the Chairman of CWB Welding Foundation, serves on the Board of Directors of New Flyer, Seaport Intermodal Inc., is an active board member of Pillar5 Pharma and the chairman of Pro Reefer and Mobile Truck Services, all of which are privately owned Canadian companies. Pillar5 Pharma is one of our previous manufacturing partners. Furthermore, he is the Founder, Chairman and Trustee of the Marinucci Family Foundation. Mr. Marinucci is a chartered accountant and a member of the Institute of Corporate Directors.

Our Board believes that Mr. Marinucci’s extensive Executive Management and Board level experience in other organizations, together with his experience of leading TSX-Listed publicly traded companies, qualifies him to serve on our Board of Directors.

Bernd Melchers Aug 8 2016 LAS8160

Bernd J. Melchers, B.A., Mr. Melchers has been a director of IntelGenx Technologies Corp. since April 2009. From January 2001 until his retirement in December 2004, Mr. Melchers was Managing Director of 3M Dyneon Holding GmbH, Germany and Global Chief Financial Officer of the worldwide operating 3M Dyneon Group, a subsidiary of 3M Corporation headquartered in Minnesota. From July 1995 to December 2000, he served as the Controller at the European Business Center of 3M Medical Markets Europe in Belgium. Prior to this, he held various senior Financial Manager positions at the Medical-Surgical Division of 3M in St. Paul, Minnesota, at 3M Health Care Products, Germany, and at 3M Pharmaceutical Products, Germany.

Our Board believes that Mr. Melchers’ 30 years of experience within the pharmaceutical and health care industry, together with his extensive hands-on international experience in corporate financial management and his extensive operational and financial expertise, as well as his track record and achievements in global financial management positions of pharmaceutical, medical and specialty chemical businesses, qualifies him to serve on our Board of Directors.

Clemens Mayr Aug 8 2016 LAS8181

Clemens Mayr Mr. Mayr has been a Director of IntelGenx Technologies Corp. since August 2015. Since 2006, he has been a partner of McCarthy Tétrault LLP, a leading Canadian law firm. Prior thereto, Mr. Mayr was partner with Ogilvy Renault LLP from 1999 to 2006 and lawyer at this firm from 1997 to 1999. He practises in the areas of securities and corporate law, particularly in domestic and cross-border mergers and acquisitions, take-over bids and public financings, and has been involved in numerous mergers and acquisitions, as well as venture capital financings. In the course of his practice, he has advised corporations and boards in numerous industries, including in particular life-sciences and technology. He also currently serves as the President and Chief Executive Officer of the Institute of Corporate Directors (Quebec Chapter).

Mr. Mayr received his LLB from the Universite de Montreal in 1990 and was called to the Quebec bar in 1991.

Since February 2017, McCarthy Tetrault LLP has been acting as the Company’s Canadian legal counsel.

Our Board believes that Mr. Mayr’s strong background and experience in corporate governance, M&A and capital markets, as well as his unique qualification to provide guidance to the Company’s executive management to execute its growth strategy, qualifies him to serve on our Board of Directors.

Mark Nawacki Aug 8 2016 LAS8167 2

Mark Nawacki, CPA, CA, Mr. Nawacki has been a Director of IntelGenx Technologies Corp. since August 2016. Prior to his appointment, from February to July 2016, Mr. Nawacki was a member of the Scientific Advisory Board of IntelGenx Corp., which provides advice to the Company’s management team. Since February 2015, Mark Nawacki has been the President and CEO of Searchlight Pharma Inc., a Canadian-based private specialty pharmaceutical company focused on the acquisition and commercialization of innovative and unique healthcare and pharmaceutical products. He is also a director of Searchlight Pharma Inc. Fom September 2003 to September 2014, Mr. Nawacki served as Executive Vice President, Business and Corporate Development of Paladin Labs, where he spent more than 11 years building out the company’s commercial and geographic footprint. During his 11-year tenure at Paladin, Mr. Nawacki helped shape the therapeutic focus of Paladin’s Canadian business via licensing and acquisitions, and built Paladin’s international expansion and emerging markets strategy.

Mr. Nawacki holds a BA in International Relations and Russian and East European Studies from the University of Toronto (Trinity), an MBA from the University of Toronto, and is a Canadian-designated CPA. He is a past member of the Board of Trustees of the Licensing Executive Society (USA & Canada) and is a former President and Board Member of the Canadian Healthcare Licensing Association. He also currently serves on the Board of Kane Biotech Inc., a Canadian Company publicly traded on the TSX Venture Exchange, the Montreal Bach Festival and The Sacred Heart School of Montreal.

Our Board believes that Mr. Nawacki’s executive management experience, various board positions, and scientific expertise as well as his life sciences industry, business development and licensing transactional experience, qualifies him to serve on our Board of Directors.

Ingrid Zerbe 2 Web Aug 16 2016

Ingrid Zerbe, Mrs. Zerbe is our Corporate Secretary since 2006. Mrs. Zerbe is the founder of IntelGenx Corp., our Canadian Subsidiary. She served as the President of IntelGenx Corp, from its incorporation in June 2003 until December 2005. She has been a Director of the subsidiary since its incorporation in June 2003 and a Director of the parent company from April 2006 until August 2006. Mrs. Zerbe was the Director, Finance and Administration of IntelGenx Corp. from 2003 to 2016. She holds a bachelor degree in economics from a business school in Bottrop, Germany, and a bachelor degree in social sciences from the University of Dortmund, Germany.